Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
- Revenue in USD (TTM)45.53bn
- Net income in USD-6.15bn
- Incorporated1933
- Employees34.10k
- LocationBristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
- Phone+1 (609) 252-4621
- Fax+1 (302) 655-5049
- Websitehttps://www.bms.com/
Mergers & acquisitions
| Acquired company | BMY:NYQ since announced | Transaction value |
|---|---|---|
| RayzeBio Inc | -20.72% | 4.21bn |
| Karuna Therapeutics Inc | -19.13% | 14.40bn |
| LianBio-Mavacamten Greater China Rights | -25.97% | 350.00m |
| Mirati Therapeutics Inc | -26.84% | 5.12bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moderna Inc | 5.15bn | -5.97bn | 62.86bn | 5.60k | -- | 4.90 | -- | 12.20 | -15.66 | -15.66 | 13.51 | 33.46 | 0.2523 | 7.78 | 8.24 | 920,178.60 | -29.22 | 20.95 | -34.13 | 29.51 | 22.43 | -- | -115.82 | 32.10 | 3.91 | -- | 0.0429 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| Zoetis Inc | 8.73bn | 2.39bn | 77.98bn | 14.10k | 32.94 | 15.44 | 27.03 | 8.93 | 5.19 | 5.19 | 18.95 | 11.07 | 0.6216 | 1.00 | 7.05 | 619,432.60 | 17.00 | 14.47 | 19.66 | 17.18 | 70.13 | 69.80 | 27.34 | 25.77 | 1.94 | 16.82 | 0.5659 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Gilead Sciences, Inc. | 27.45bn | 484.00m | 82.44bn | 18.00k | 184.02 | 4.70 | 25.75 | 3.00 | 0.3596 | 0.3596 | 21.89 | 14.08 | 0.4646 | 3.88 | 6.22 | 1,525,000.00 | 0.7718 | 6.74 | 0.9624 | 8.12 | 75.78 | 78.64 | 1.66 | 16.95 | 0.9365 | 13.67 | 0.5907 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Bristol-Myers Squibb Co | 45.53bn | -6.15bn | 84.21bn | 34.10k | -- | 5.11 | 22.59 | 1.85 | -3.10 | -3.10 | 22.15 | 8.14 | 0.4711 | 3.92 | 5.18 | 1,335,308.00 | -6.35 | 3.05 | -8.27 | 3.76 | 75.94 | 76.13 | -13.47 | 7.69 | 0.9947 | 15.57 | 0.7709 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Regeneron Pharmaceuticals Inc | 13.10bn | 3.86bn | 108.04bn | 13.45k | 28.96 | 4.00 | 25.17 | 8.25 | 33.86 | 33.86 | 114.89 | 244.93 | 0.4067 | 0.6974 | 2.53 | 973,985.10 | 11.98 | 20.18 | 13.36 | 23.22 | 86.32 | 86.63 | 29.45 | 38.11 | 4.51 | -- | 0.091 | -- | 7.76 | 14.34 | -8.87 | 10.72 | 19.32 | -- |
| Vertex Pharmaceuticals Incorporated | 10.19bn | 4.02bn | 116.33bn | 5.40k | 29.24 | 6.28 | 27.60 | 11.42 | 15.42 | 15.42 | 39.06 | 71.80 | 0.4749 | 1.98 | 6.10 | 1,886,111.00 | 18.74 | 19.92 | 22.29 | 23.64 | 86.86 | 87.67 | 39.46 | 35.85 | 3.29 | -- | 0.0191 | 0.00 | 10.51 | 26.49 | 8.96 | 46.50 | 22.02 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 176.90m | 8.73% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 105.89m | 5.22% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 91.57m | 4.52% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 70.20m | 3.46% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 60.98m | 3.01% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 53.72m | 2.65% |
| Geode Capital Management LLCas of 31 Mar 2024 | 41.30m | 2.04% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 31.17m | 1.54% |
| PRIMECAP Management Co.as of 31 Mar 2024 | 23.27m | 1.15% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 21.06m | 1.04% |
